 Proactive Investors UK | Cellmid moves closer to royalty revenues in 2H 2013 Proactive Investors UK The first licensing agreement with Quest Diagnostics (NYSE: DGX) for the midkine lung cancer diagnostic is expected to develop into an annualised multi-million dollar royalty revenue stream, and the second licensing agreement with Pacific Edge (NZSX ... |
